Legal & General Group’s Aimmune Therapeutics AIMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-28,450
| Closed | -$980K | – | 3521 |
|
|
2020
Q3 | $980K | Sell |
28,450
-2,017
| -7% | -$43K | ﹤0.01% | 2035 |
|
|
2020
Q2 | $509K | Buy |
30,467
+401
| +1% | +$6.81K | ﹤0.01% | 2166 |
|
|
2020
Q1 | $434K | Sell |
30,066
-2,114
| -7% | -$54K | ﹤0.01% | 2112 |
|
|
2019
Q4 | $1.08M | Buy |
32,180
+12,630
| +65% | +$353K | ﹤0.01% | 2046 |
|
|
2019
Q3 | $409K | Hold |
19,550
| – | – | ﹤0.01% | 2199 |
|
|
2019
Q2 | $407K | Buy |
19,550
+1,069
| +6% | +$22K | ﹤0.01% | 2183 |
|
|
2019
Q1 | $413K | Buy |
18,481
+208
| +1% | +$4.9K | ﹤0.01% | 2192 |
|
|
2018
Q4 | $437K | Buy |
18,273
+4,123
| +29% | +$107K | ﹤0.01% | 2145 |
|
|
2018
Q3 | $386K | Hold |
14,150
| – | – | ﹤0.01% | 2194 |
|
|
2018
Q2 | $381K | Buy |
14,150
+48
| +0.3% | +$1.47K | ﹤0.01% | 2165 |
|
|
2018
Q1 | $449K | Buy |
14,102
+5,015
| +55% | +$176K | ﹤0.01% | 2136 |
|
|
2017
Q4 | $346K | Buy |
9,087
+132
| +1% | +$4.26K | ﹤0.01% | 2181 |
|
|
2017
Q3 | $221K | Buy |
8,955
+1,179
| +15% | +$25.4K | ﹤0.01% | 2314 |
|
|
2017
Q2 | $160K | Buy |
7,776
+1,634
| +27% | +$31.2K | ﹤0.01% | 2384 |
|
|
2017
Q1 | $134K | Sell |
6,142
-96
| -2% | -$1.97K | ﹤0.01% | 2408 |
|
|
2016
Q4 | $128K | Buy |
6,238
+2,489
| +66% | +$50.9K | ﹤0.01% | 2412 |
|
|
2016
Q3 | $54K | Sell |
3,749
-4,527
| -55% | -$61.1K | ﹤0.01% | 2490 |
|
|
2016
Q2 | $92K | Buy |
+8,276
| New | +$112K | ﹤0.01% | 2145 |
|
Legal & General Group's AIMT Position: Q4 2020 in Review
Legal & General Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 28,450 shares — an estimated $980K sold.
Legal & General Group first reported a position in AIMT in Q2 2016 and held it in 18 quarters. The position peaked at $1.08M in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.
- Legal & General Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
- Legal & General Group sold 28,450 Aimmune Therapeutics shares in Q4 2020, an estimated $980K.
- Legal & General Group first reported a position in Aimmune Therapeutics in Q2 2016 and held it in 18 quarters.
- Legal & General Group's Aimmune Therapeutics position peaked at $1.08M in Q4 2019.
- 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.
Based on Legal & General Group's 13F filing for Q4 2020, filed 12 Feb 2021.